Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02628236 · ClinicalTrials.gov registry record · Phase 2
Maximal Use Systemic Exposure Study of Levulan Kerastick (MUSE 2)
A Phase 2 study of Keratosis, Actinic, sponsored by DUSA Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
- 2
- Study locations
NCT02628236: Completed Phase 2 study of Keratosis, Actinic, sponsored by DUSA Pharmaceuticals.
NCT02628236 is a Phase 2 study of Keratosis, Actinic that has completed, run by DUSA Pharmaceuticals. The registered enrollment target is 14 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02628236, a Phase 2 study of Keratosis, Actinic, has completed, sponsored by DUSA Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to evaluate the potential for systemic exposure of aminolevulinic acid (ALA) and protoporphyrin IX (PpIX) when applied topically under occlusion, in a maximal use setting in patients with multiple actinic keratoses (AK) involving the upper extremities.
Primary Outcome
Maximum baseline corrected plasma concentration (Cmax) for ALA over the 24 hour sampling time period. Blood samples were taken before ALA application and at 15 and 30 minutes, 1, 2, 4, 8, 12, 16, 24, 36 and 48 hours following study medication application.
Conditions Studied
Interventions
- DRUG Aminolevulinic Acid (ALA)
- DEVICE BLU-U
Study Locations (2)
Texas
- DermResearch, Inc. - Austin
- J&J Studies, Inc - College Station
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2016-02 |
| Est. Completion | 2016-07 |
| Phase | Phase 2 |
What the finished NCT02628236 record still lists
NCT02628236 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Keratosis, Actinic appearing as the primary indexed condition, and to 2 interventions - of which Aminolevulinic Acid (ALA) is the first listed.
NCT02628236 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT02628236 about?
NCT02628236 is a clinical study titled "Maximal Use Systemic Exposure Study of Levulan Kerastick (MUSE 2)". The purpose of this study is to evaluate the potential for systemic exposure of aminolevulinic acid (ALA) and protoporphyrin IX (PpIX) when applied topically under occlusion, in a maximal use setting in patients with multiple actinic keratoses (AK) involving the upper extremities.
What is the current status of trial NCT02628236?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2016-02. Estimated completion is 2016-07.
What conditions does trial NCT02628236 study?
This clinical trial studies the following conditions: Keratosis, Actinic.
What interventions are being tested in trial NCT02628236?
The interventions under investigation include: Aminolevulinic Acid (ALA) (DRUG), BLU-U (DEVICE).
Who is sponsoring clinical trial NCT02628236?
This trial is sponsored by DUSA Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02628236 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Keratosis, Actinic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02628236's enrollment target sits among peer trials
14 1941st of 2000 higher than 54 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia